{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:33:28Z","timestamp":1789774408231,"version":"4.0.1"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Penile cancer is a rare malignancy, and treatment options for advanced stages are limited, often yielding unsatisfactory outcomes. This prospective, multicenter, phase 1 clinical study was conducted to evaluate the preliminary safety, tolerability, and antitumor activity of the anti\u2010epidermal growth factor receptor (EGFR) monoclonal antibody CDP1 in combination with chemotherapy, in patients with penile cancer. The trial comprised two parts: a 3\u2009+\u20093 dose\u2010escalation CDP1 monotherapy study to determine the dose for the combination study, in which 12 patients with advanced solid tumors received CDP1 alone, and a CDP1\u2010chemotherapy combination study, in which 20 patients with recurrent or metastatic penile cancer received CDP1 combined with the paclitaxel\u2010ifosfamide\u2010cisplatin regimen (TIP). CDP1 monotherapy and combination treatment were well tolerated, and the maximum tolerated dose was not reached. The most common treatment\u2010related adverse events for CDP1 monotherapy included rash (83%), dry skin (50%), and hypomagnesemia (50%), while for CDP1 combined with chemotherapy, they were anemia (85%), nausea (80%), and white blood cell decreased (80%). Among penile cancer patients receiving the combination therapy, the objective response rate was 74%, tumor downstaging enabled surgery in seven patients (35%), and the median progression\u2010free survival was 6.9\u2009months. In conclusion, the combination of an anti\u2010EGFR monoclonal antibody and chemotherapy was well tolerated and showed potential efficacy in penile cancer, supporting further investigation.<\/jats:p>","DOI":"10.1002\/ijc.70249","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:52:21Z","timestamp":1763038341000},"page":"2186-2194","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti\u2010epidermal growth factor receptor monoclonal antibody combined with chemotherapy in penile cancer: A prospective, multicenter, phase 1 study"],"prefix":"10.1002","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-6343","authenticated-orcid":false,"given":"Pei","family":"Shu","sequence":"first","affiliation":[{"name":"Cancer Center West China Hospital, Sichuan University  Chengdu Sichuan China"},{"name":"Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs West China Hospital, Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-2678","authenticated-orcid":false,"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center West China Hospital, Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Urology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengchuan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Urology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College, Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luo","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital, Chongqing Cancer Hospital Chongqing Cancer Research Institute, Chongqing Cancer Center  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-5888","authenticated-orcid":false,"given":"Hui","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Urology, State Key Laboratory of Oncology in South China Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Urology, State Key Laboratory of Oncology in South China Sun Yat\u2010sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Dragonboat Biopharmaceutical, Co., Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-4824","authenticated-orcid":false,"given":"Li","family":"zheng","sequence":"additional","affiliation":[{"name":"Cancer Center West China Hospital, Sichuan University  Chengdu Sichuan China"},{"name":"Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs West China Hospital, Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-5481","authenticated-orcid":false,"given":"Ji\u2010yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center West China Hospital, Sichuan University  Chengdu Sichuan China"},{"name":"Department of Biotherapy, Cancer Center West China Hospital, Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00557-y"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4802"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.12.049"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.07.012"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062175"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00231-3"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2009.07448.x"},{"key":"e_1_2_12_9_1","first-page":"32s","article-title":"The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia","volume":"19","author":"Arteaga CL","year":"2001","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3282f23287"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000024"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.5477"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1542"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12360"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.08.002"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.993377"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12450"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656"},{"key":"e_1_2_12_21_1","first-page":"e247074","article-title":"First\u2010line PD\u20101 blockade combined with chemotherapy for stage IV penile squamous cell carcinoma: a multicenter retrospective study","volume":"23","author":"Xiong L","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5009"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15828"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.023"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2389-8"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00617-x"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70249","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:53:44Z","timestamp":1773014024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,15]]}},"alternative-id":["10.1002\/ijc.70249"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70249","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"2025-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}